Compare prices and buy Cagrilintide from 37 research peptide vendors - also called suppliers or sources. Updated daily.
A long-acting 37-amino-acid synthetic analog of the pancreatic hormone amylin (CAS 1415456-99-3), developed by Novo Nordisk. It activates amylin and calcitonin receptors non-selectively, a satiety pathway separate from and complementary to GLP-1 signaling. Combined with semaglutide in CagriSema. Novo Nordisk has filed the combination for FDA approval. Cagrilintide monotherapy remains investigational.
For research purposes only. Not medical advice.
Cagrilintide (Novo Nordisk's AM833, also coded NN0174-0833) is a long-acting analog of amylin, the 37-residue hormone co-secreted with insulin by pancreatic beta cells. It is built on the peptide backbone of pramlintide (the amylin analog the FDA approved as Symlin in 2005) with three amino-acid substitutions and a C20 fatty-diacid chain attached at the N-terminal lysine. The acylation binds albumin and makes cagrilintide long-acting, where pramlintide has a half-life of about 48 minutes in healthy individuals, according to the Symlin label. The substitutions reduce the amyloid-fibril aggregation that made native human amylin difficult to develop as a drug.
Its receptor pharmacology places it outside the incretin class. Cagrilintide is a non-selective agonist of the calcitonin receptor family (the amylin receptors AMY1R through AMY3R, plus the calcitonin receptor itself), signaling satiety through amylin receptors in the hindbrain and hypothalamus. Semaglutide, tirzepatide and retatrutide act on GLP-1 and related incretin receptors, a separate family. That independence is the stated rationale for combining the two mechanisms. Cagrilintide is catalogued alongside the incretins here on commercial grounds alone.
Nearly all published Phase 3 data covers CagriSema, the fixed-dose combination of cagrilintide with semaglutide, rather than cagrilintide alone.
A separate Phase 3 program, REIMAGINE, tested the combination for glycemic control in type 2 diabetes, and Novo Nordisk announced headline results from REIMAGINE 2 on February 2, 2026.
Novo Nordisk submitted a New Drug Application to the FDA on December 18, 2025 for CagriSema in weight management for adults with obesity, or with overweight plus at least one weight-related comorbid condition. As of October 21, 2026, Drugs@FDA lists no approval for the combination or for cagrilintide alone.
Cagrilintide by itself is not part of that filing. Its monotherapy Phase 3 program, RENEW, began on November 5, 2025, and the first trial's primary completion is scheduled for May 2027.
The compounding question that dominates the regulatory picture for older research peptides is also settled for cagrilintide. Cagrilintide has no USP monograph, is not a component of an FDA-approved drug and appears in neither of FDA's bulk-substance nomination lists (503A, updated May 14, 2026, and 503B, updated March 21, 2025), so it is not eligible for use by a 503A compounding pharmacy or a 503B outsourcing facility. The FDA bulk-substance proceedings (the Category 2 designations, the April 2026 removals, the July 2026 Pharmacy Compounding Advisory Committee docket) concern nominated substances, and cagrilintide's absence from them reflects no FDA finding about the compound.
Vendors sell cagrilintide both alone and pre-mixed with an incretin. Semaglutide + cagrilintide mirrors the composition Novo Nordisk carried through Phase 3. Retatrutide + cagrilintide has no clinical counterpart: retatrutide is an Eli Lilly compound, no controlled human trial has evaluated the pairing, and the combination is simply a market convention.
Blend prices are also not directly comparable to single-compound vials. A blend listing's size is the total peptide in the vial across both components, so its per-milligram figure belongs against a component-weighted average, not against a cagrilintide vial of the same stated size.
Cagrilintide sits outside the "GLP-N" generational code family (GLP1 for semaglutide, GLP2 for tirzepatide, GLP3 for retatrutide) because it is not a GLP-1 analog. Vendors instead abbreviate the name directly, as with Cagri, Cag, CAG-4 and EZP-CG, or extend a house code family: SA-4C shares a prefix with SA-2T for tirzepatide and SA-3R for retatrutide, where the numeral continues the generational counter and the letter names the compound. Unlike retatrutide codes such as R-30 and R-10, that numeral has nothing to do with vial size.
PeptideScouter verifies listings against the published CAS number (1415456-99-3) or molecular formula (C194H312N54O59S2) before mapping them, and indexes every mapped listing per milligram so vendors stay comparable.
No. Cagrilintide is a single compound, an amylin analog. CagriSema is Novo Nordisk's fixed-dose combination product pairing cagrilintide with semaglutide. Nearly every Phase 3 efficacy figure quoted for cagrilintide, including those from REDEFINE 1, comes from the combination rather than from cagrilintide by itself. Cagrilintide monotherapy entered its own Phase 3 program, RENEW, in November 2025.
No. Cagrilintide is an amylin analog and a non-selective agonist of the calcitonin receptor family, including the amylin receptors AMY1R through AMY3R. Semaglutide, tirzepatide and retatrutide act on GLP-1 and related incretin receptors, an entirely separate receptor family. Cagrilintide is grouped with those compounds on PeptideScouter because vendors sell and blend them together, not because they share a mechanism.
No. Novo Nordisk submitted a New Drug Application for the CagriSema combination on December 18, 2025. As of October 21, 2026, Drugs@FDA lists no approval for the combination or for cagrilintide alone. Cagrilintide is also not eligible for compounding by a licensed pharmacy or outsourcing facility, because it has no USP monograph, is not a component of an FDA-approved drug and appears in neither of FDA's bulk-substance nomination lists. Material sold by research vendors is research-grade and offered for laboratory use only, not for human consumption.
The semaglutide blend mirrors CagriSema, the fixed-dose combination Novo Nordisk carried through Phase 3. The retatrutide blend has no clinical counterpart: retatrutide is an Eli Lilly investigational compound and no controlled human trial has evaluated the two together. Blend pricing is not directly comparable either, because a blend vial's stated size is the total across both components rather than the amount of either one.
Pramlintide, approved by the FDA as Symlin in 2005, is a short-acting amylin analog with a half-life of about 48 minutes in healthy individuals, according to its label. Cagrilintide uses the same peptide backbone with three amino-acid substitutions and a fatty-diacid chain at the N-terminus, which binds albumin and makes it long-acting. The substitutions also reduce the amyloid-fibril formation of native amylin that had long complicated its development as a drug.
Cagrilintide is sold by 37 research peptide vendors indexed on PeptideScouter, with 69 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
33 of the 37 indexed vendors currently have Cagrilintide in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Studz Peptides currently lists Cagrilintide at $3.50/mg, the lowest listed price across 37 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $3.15/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 37 vendors listing Cagrilintide publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $3.50/mg listed to $3.15/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
Cagrilintide ranges from $3.50/mg to $21.60/mg across 69 listings from 37 research peptide vendors, normalized to USD per milligram and refreshed daily.
37 research peptide vendors currently list Cagrilintide on PeptideScouter, with 33 in stock right now. We track 69 listings across size and kit variants.
Cagrilintide's CAS Registry Number is 1415456-99-3. It is also sold as SA-4C, Cagri, Cag.
